News Medigene AG

Equities

MDG1

DE000A1X3W00

Market Closed - Xetra Other stock markets 11:36:05 2024-04-25 am EDT			5-day change	1st Jan Change
1.595 ^EUR	+0.31%		-13.55%	+4.59%

Apr. 08	Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	CI
Apr. 04	Medigene Gets European Patent for T-Cell Receptor Technology	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medigene presents streamlined 6-day, high stemness TCR-T therapy production process	Apr. 25	GL
Medigene to Present at Upcoming Scientific Conferences	Apr. 17	GL
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	Apr. 08	GL
Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	Apr. 08	CI
Medigene Gets European Patent for T-Cell Receptor Technology	Apr. 04	MT
Medigene AG Secures European Patent for its iM-TCR Technology	Apr. 04	GL
Medigene AG Secures European Patent for Its iM-TCR Technology	Apr. 04	CI
Medigene AG Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Transcript : Medigene AG, 2023 Earnings Call, Mar 28, 2024	Mar. 28
Medigene : Statement on Corporate Governance 2023	Mar. 28	PU
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update	Mar. 28	GL
Medigene Ag Provides Earnings Guidance for 2024	Mar. 28	CI
Medigene : Declaration of Conformity 2024	Mar. 26	PU
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	Mar. 19	GL
Medigene AG to report full year 2023 financial results on March 28, 2024	Mar. 18	GL
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting	Mar. 06	GL
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo	Mar. 04	GL
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo	Mar. 04	AQ
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy	Mar. 04	CI
Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies	Feb. 29	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Medigene AG

Equities

MDG1

DE000A1X3W00

Summary

Filters